Advertisement Press Releases Archive - Page 145 of 231 - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Pressreleases

  • Hybrigenics renews a services contract for a total of USD 2.4 million

    Hybrigenics (ALHYG), a bio-pharmaceutical company listed on Alternext (NYSE-Euronext) in Paris, announces today that Hybrigenics Services, its fully-owned subsidiary specialised in protein interactions, has renewed a 3-year research services agreement worth USD 2.4 million with an American life sciences company.

  • Realize cost savings with new DisiTest 50 disintegration tester

    Performing disintegration tests has mostly remained a time-consuming task where results are recorded manually and unproductive waiting & cleaning times represent a significant portion of daily machine utilization. The new DisiTest 50 disintegration tester from Dr. Schleuniger® Pharmatron incorporates innovative induction heating technology and combines it with the benefits of automation to realize cost savings by significantly streamlining the disintegration testing process.

  • Smart, Smarter, SmartTest 50

    The SmartTest 50 sets new standards in semi-automatic testing of up to 5 physical parameters (weight, thickness, width, diameter/length, and hardness) of virtually all tablet shapes with one single unit. In full compliance with current Pharmacopeia requirements, the system offers highest precision, flexibility and exceptional user-friendliness.

  • PPCE Announces Strategic Partnership With ECLINSO AG

    PPCE, a high-quality Clinical Data Management services company providing CDISC-certified services announced today that it has entered into a strategic partnership agreement with ECLINSO AG, a leading provider of eClinical information technology, consulting and business process outsourcing services.

  • PharmaTelevision Interview to Spotlight Aptalis Pharma’s Year in Review

    FDA approvals, revenue gain and organic business growth are just a few of the topics that John Fraher, President, Aptalis Pharma, addresses during an on-air interview with Fintan Walton, CEO, PharmaVentures and PharmaTelevision. The interview, conducted during BIO 2012 in Boston, reflects Fraher’s commentary regarding the integration of companies post Axcan Intermediate Holdings’ acquisition of Eurand N.V. in 2011.